Author Archives: Jose Marques Lopes PhD

Adempas May Benefit PAH Patients Who Fail to Respond to PDE5 Inhibitors, Trial Indicates

Bayer’s Adempas (riociguat) can improve the lung and heart functioning of pulmonary hypertension patients who fail to respond to phosphodiesterase-5 inhibitors (PDE5i), a Phase 3 clinical trial suggests. The RESPITE trial also showed that Adempas can improve biomarkers of pulmonary arterial hypertension, or PAH. Researchers published the study in the European…

Early Renal Denervation Improves Pulmonary Hypertension and Survival Rate, Animal Study Shows

Early renal denervation (RDN) treatment improved pulmonary arterial hypertension (PAH) in a rat model, a new study from China showed. The study titled, “Effects of renal denervation on monocrotaline induced pulmonary remodeling,” was published in the journal Oncotarget. Despite the progress achieved with oral therapies over the last two decades, the prognosis…

Pulmonary Hypertension Patients Like Implanted Remodulin Delivery System

Pulmonary arterial hypertension (PAH) patients have given high marks to a new implanted,  programmable intravenous (IV) system that delivered Remodulin (treprostinil) to them with few complications, according to a clinical trial. The study, “Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System…

Pulmonary Thromboendarterectomy Should Be Considered for PH Before Transplant, Case Report Contends

Chronic thromboembolic pulmonary hypertension (CTEPH) may be mitigated by pulmonary thromboendarterectomy, which prevents the need for lung transplant, a new case report shows. The study, “Pulmonary Thromboendarterectomy for Pulmonary Hypertension Before Considering Transplant,” appeared in The Ochsner Journal. CTEPH is observed in approximately 4% of cases…